Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.73 |
| ▸ | PNMT | P11086 | 3/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16814939 | 0.87 | DPP4 (0.59) | DPP4PNMTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3790601 | 0.87 | ALDH1A1 (0.62) | DPP4PNMTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2455127 | 0.85 | DPP4 (0.57) | DPP4PNMTTAAR1 | |
| SCHEMBL2482120 | 0.85 | DPP4 (0.57) | DPP4PNMTLOXL2CSNK2A2CSNK2B | |
| SCHEMBL6862516 | 0.85 | DPP4 (1.00) | DPP4PNMTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL29872374 | 0.84 | DPP4 (1.00) | DPP4PNMTLOXL2CSNK2A1TAAR1 | |
| SCHEMBL469051 | 0.84 | DPP4 (1.00) | DPP4PNMTLOXL2CSNK2A1TAAR1 | |
| Hydrochloric Acid SCHEMBL29502692 | 0.83 | DPP4 (0.79) | DPP4PNMTCSNK2A1TAAR1CYP2A6 | |
| SCHEMBL3805255 | 0.83 | DPP4 (0.55) | DPP4PNMTLOXL2CSNK2A2CSNK2B | |
| SCHEMBL28455208 | 0.83 | DPP4 (0.55) | DPP4PNMTLOXL2CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841471-B1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS | GRACE W R & CO (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190153135-A1 | Activator Compositions, Their Preparation, And Their Use In Catalysts | GRACE W R & CO (US) | 2019-05-23 | — | — | US | disclosed |
| US-10221264-B2 | Activator compositions, their preparation, and their use in catalysts | W. R. GRACE & CO.-CONN. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150105238-A1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS | W. R. GRACE & CO.-CONN. | 2015-04-16 | — | — | US | disclosed |
| EP-2643366-B1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS | ALBEMARLE CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2841471-A1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS | Albemarle Corporation (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8895465-B2 | Activator compositions, their preparation, and their use in catalysis | ALBEMARLE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2013162745-A1 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS | ALBEMARLE CORPORATION (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2643366-A2 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS | Albemarle Corporation (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130253155-A1 | Activator Compositions, Their Preparation, and Their Use In Catalysis | ALBEMARIE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012071205-A2 | ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS | ALBEMARLE CORPORATION (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | DPP4 3267/4885PNMT 709/4885LOXL2 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.